Biotechnology VALUE FUND II L.P., Director at Kymera Therapeutics, Inc. (KYMR), bought 82,014 shares at $29.89 ($2.5M) on 2023-01-11, disclosed to the SEC on 2023-01-13.
Open-market purchase of $2.5M KYMR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.89 | 10,961 | $328K | 13.1% |
| 2 | $29.89 | 10,961 | $328K | 13.1% |
| 3 | $29.89 | 11,149 | $333K | 13.3% |
| 4 | $29.89 | 11,149 | $333K | 13.3% |
| 5 | $31.24 | 2,985 | $93K | 3.7% |
| 6 | $31.24 | 2,985 |
| $93K |
| 3.7% |
| 7 | $31.24 | 15,912 | $497K | 19.9% |
| 8 | $31.24 | 15,912 | $497K | 19.9% |
| Total | $30.51 avg | 82,014 | $2.5M | 100% |
| Filing → |
| KYMR | BUY | 2022-08-23 | $14.2M | — | Filing → |
| RPTX | BUY | 2022-06-15 | $3.8M | — | Filing → |
| RPTX | BUY | 2022-01-21 | $28.1M | — | Filing → |